Nicotine / THR - Guides for Policymakers & Advocates: Difference between revisions
Jump to navigation
Jump to search
Richardpruen (talk | contribs) (Marked this version for translation) |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
<br> | |||
<br> | |||
<br> | |||
[[file:Tobacco Harm Reduction.png|center]] | |||
<br> | |||
<br> | |||
{{TOC limit|3}} | |||
<br> | |||
<br> | |||
<languages/> | <languages/> | ||
<translate> | <translate> | ||
=Advocates= <!--T:1--> | =Advocates= <!--T:1--> | ||
===[https://healthdiplomats.com/THR_Downloads/Tobacco_Harm_Reduction_2020.pdf Saving Lives - An Advocates Guide To Tobacco Harm Reduction]=== <!--T:2--> | ===[https://healthdiplomats.com/THR_Downloads/Tobacco_Harm_Reduction_2020.pdf Saving Lives - An Advocates Guide To Tobacco Harm Reduction]=== <!--T:2--> | ||
| Line 11: | Line 20: | ||
= | =Educational Materials= <!--T:4--> | ||
| Line 20: | Line 28: | ||
*By: Clive Bates / The counterfactual | *By: Clive Bates / The counterfactual | ||
*"Welcome, this is my (Clive) 2020 Q & A on nicotine science and policy. It mostly focusses on nicotine vaping as an alternative to smoking, but most of the argument also applies to heated tobacco products, modern smokeless tobacco and new oral nicotine products. It consists of about 60 questions and builds on a brief [https://www.clivebates.com/vaping-policy-rapid-questions-and-answers/ Q & A that I submitted to a consultation], a critique of an absurd [https://www.clivebates.com/world-health-organisation-fails-at-science-and-fails-at-propaganda-the-sad-case-of-whos-anti-vaping-qa/ anti-vaping Q & A by the WHO] and my [https://www.clivebates.com/vaping-risk-compared-to-smoking-challenging-false-dangerous-claim-by-stanton-glantz/ critique of numerous false and misleading claims made by Professor Stanton Glantz]." | *"Welcome, this is my (Clive) 2020 Q & A on nicotine science and policy. It mostly focusses on nicotine vaping as an alternative to smoking, but most of the argument also applies to heated tobacco products, modern smokeless tobacco and new oral nicotine products. It consists of about 60 questions and builds on a brief [https://www.clivebates.com/vaping-policy-rapid-questions-and-answers/ Q & A that I submitted to a consultation], a critique of an absurd [https://www.clivebates.com/world-health-organisation-fails-at-science-and-fails-at-propaganda-the-sad-case-of-whos-anti-vaping-qa/ anti-vaping Q & A by the WHO] and my [https://www.clivebates.com/vaping-risk-compared-to-smoking-challenging-false-dangerous-claim-by-stanton-glantz/ critique of numerous false and misleading claims made by Professor Stanton Glantz]." | ||
| Line 28: | Line 35: | ||
*Quick 1 page guide | *Quick 1 page guide | ||
*All references are hyperlinked to official WHO and government reports, and peer-reviewed studies | *All references are hyperlinked to official WHO and government reports, and peer-reviewed studies | ||
| Line 37: | Line 43: | ||
===TPA Series: [https://www.protectingtaxpayers.org/thr-101/ THR 101]=== | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Cessation.pdf Cessation] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Dual-Use.pdf Dual Use] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Role-of-Flavors.pdf Flavors] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-THR.pdf Harm Reduction] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Heated-Tobacco.pdf Heated Tobacco (aka: HTP, HnB)] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Popcorn-Lung.pdf Popcorn Lung] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/Tobacco-Vaping-101-Nicotine-Pouches.pdf Nicotine Pouches] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Snus.pdf Snus] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Vaping-Injuries.pdf Vaping Lung Injuries (aka: EVALI)] | |||
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Youth-Reasons.pdf Youth Use Reasons] | |||
===[https://www.protectingtaxpayers.org/harm-reduction/tobacco-vaping-101-50-state-analysis/ Tobacco & Vaping 101: 50 State Analysis]=== | |||
<br> | |||
===[https://www.thr101.org/tobacco-harm-reduction-101-guideboo TOBACCO HARM REDUCTION 101: A GUIDEBOOK FOR POLICYMAKERS]=== <!--T:11--> | ===[https://www.thr101.org/tobacco-harm-reduction-101-guideboo TOBACCO HARM REDUCTION 101: A GUIDEBOOK FOR POLICYMAKERS]=== <!--T:11--> | ||
| Line 42: | Line 63: | ||
<!--T:12--> | <!--T:12--> | ||
*Written by Lindsey Stroud - Webmaster of [https://www.thr101.org/ Tobacco Harm Reduction 101] | *Written by Lindsey Stroud - Webmaster of [https://www.thr101.org/ Tobacco Harm Reduction 101] | ||
===[https://www.atr.org/tholos-foundation-releases-vaping-tobacco-harm-reduction-the-path-to-saving-millions-of-lives-2023-report/ Vaping & Tobacco Harm Reduction: The Path to Saving Millions of Lives]=== | |||
<br> | |||
=Why= <!--T:13--> | =Why= <!--T:13--> | ||
| Line 51: | Line 76: | ||
<!--T:15--> | <!--T:15--> | ||
*Written by INNCO - [https://innco.org/ International Network of Nicotine Consumer Organisations] - 2021 | *Written by INNCO - [https://innco.org/ International Network of Nicotine Consumer Organisations] - 2021 | ||
| Line 59: | Line 83: | ||
*Written by Michelle Minton - Competitive Enterprises Institute - 2018 | *Written by Michelle Minton - Competitive Enterprises Institute - 2018 | ||
</translate> | </translate> | ||
=Promoting Harm Reduction Policies= | |||
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/ Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study]=== | |||
*The simulation suggests that the promotion of e-cigarettes as a harm-reduction policy is a viable strategy, given current evidence that e-cigarettes offset or divert from smoking. Given the strong effects of implementation challenges on policy effectiveness in the short term, accurately modeling such obstacles can usefully inform policy design. | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/pdf/12954_2021_Article_484.pdf PDF Version] | |||
*Citation: Selya AS. Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study. Harm Reduct J. 2021;18(1):36. Published 2021 Mar 20. doi:10.1186/s12954-021-00484-6 | |||
*Acknowledgement: This work was supported by the National Institute for General Medical Sciences (NIGMS) within the National Institutes of Health (NIH), grant number P20GM121341; by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU), grant number NNA-2016/10023. After the initial submission of this manuscript, AS became employed by Pinney Associates, Inc. which provides consulting services on tobacco harm minimization to JUUL Labs, Inc. The content presented here precedes this competing interest, and JUUL Labs, Inc. and PinneyAssociates, Inc. had any role in the conceptualization, design, analysis, interpretation, or presentation of data, nor in the decision to publish. | |||
Latest revision as of 09:36, 12 July 2023
Advocates
Saving Lives - An Advocates Guide To Tobacco Harm Reduction
- Written by AHRA - Africa Harm Reduction Alliance - 2020
Educational Materials
Nicotine science and policy Q & A
- By: Clive Bates / The counterfactual
- "Welcome, this is my (Clive) 2020 Q & A on nicotine science and policy. It mostly focusses on nicotine vaping as an alternative to smoking, but most of the argument also applies to heated tobacco products, modern smokeless tobacco and new oral nicotine products. It consists of about 60 questions and builds on a brief Q & A that I submitted to a consultation, a critique of an absurd anti-vaping Q & A by the WHO and my critique of numerous false and misleading claims made by Professor Stanton Glantz."
E-CIGARETTE POLICY BRIEF: Seven Things Policy Makers Need to Know
- Quick 1 page guide
- All references are hyperlinked to official WHO and government reports, and peer-reviewed studies
A Blueprint for Better Regulation
- Written by UKVIA - UK Vaping Industry Association - 2021
TPA Series: THR 101
- Cessation
- Dual Use
- Flavors
- Harm Reduction
- Heated Tobacco (aka: HTP, HnB)
- Popcorn Lung
- Nicotine Pouches
- Snus
- Vaping Lung Injuries (aka: EVALI)
- Youth Use Reasons
Tobacco & Vaping 101: 50 State Analysis
TOBACCO HARM REDUCTION 101: A GUIDEBOOK FOR POLICYMAKERS
- Written by Lindsey Stroud - Webmaster of Tobacco Harm Reduction 101
Vaping & Tobacco Harm Reduction: The Path to Saving Millions of Lives
Why
10 reasons why blanket bans of e-cigarettes and HTPs in low- and middle-income countries (LMICs) are not fit for purpose
- Written by INNCO - International Network of Nicotine Consumer Organisations - 2021
Fear Profiteers: How E-cigarette Panic Benefits Health Activists
- Written by Michelle Minton - Competitive Enterprises Institute - 2018
Promoting Harm Reduction Policies
- The simulation suggests that the promotion of e-cigarettes as a harm-reduction policy is a viable strategy, given current evidence that e-cigarettes offset or divert from smoking. Given the strong effects of implementation challenges on policy effectiveness in the short term, accurately modeling such obstacles can usefully inform policy design.
- PDF Version
- Citation: Selya AS. Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study. Harm Reduct J. 2021;18(1):36. Published 2021 Mar 20. doi:10.1186/s12954-021-00484-6
- Acknowledgement: This work was supported by the National Institute for General Medical Sciences (NIGMS) within the National Institutes of Health (NIH), grant number P20GM121341; by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU), grant number NNA-2016/10023. After the initial submission of this manuscript, AS became employed by Pinney Associates, Inc. which provides consulting services on tobacco harm minimization to JUUL Labs, Inc. The content presented here precedes this competing interest, and JUUL Labs, Inc. and PinneyAssociates, Inc. had any role in the conceptualization, design, analysis, interpretation, or presentation of data, nor in the decision to publish.